(Q41114408)

26 September 2017

title

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: Labetalol (English)

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Cardiology and cardiovascular medicine

27 June 2022

main subject

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

27 June 2022

author name string

W. Frishman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A386753

27 June 2022

S. Halprin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A386753

27 June 2022

language of work or name

English

0 references

publication date

1 November 1979

1 reference

full work available at URL

26 September 2017

https://api.elsevier.com/content/article/PII:0002870379902941?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

https://api.elsevier.com/content/article/PII:0002870379902941?httpAccept=text/plain

27 June 2022

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

27 June 2022

published in

American Heart Journal

1 reference

26 September 2017

volume

98

1 reference

26 September 2017

issue

5

1 reference

26 September 2017

page(s)

660-665

1 reference

A study of the adrenotropic receptors

26 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors

17 April 2023

2

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man

17 April 2023

3

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

17 April 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Effects of beta-adrenergic receptor blockade on airway conductance and lung volume in normal and asthmatic subjects.

17 April 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Evidence for existence of alpha-adrenergic receptors in the mammalian trachea

17 April 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Letter: Alpha-receptor-blocking drugs in bronchial asthma

17 April 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Effects of phentolamine inhalation on patients with bronchial asthma

17 April 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man

17 April 2023

11

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma

17 April 2023

15

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade

17 April 2023

17

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects

17 April 2023

19

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Labetalol in long-term treatment of hypertension

17 April 2023

23

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Labetalol in resistant hypertension

17 April 2023

24

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Acute effect of intravenous labetalol in the treatment of systemic arterial hypertension

17 April 2023

29

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol

17 April 2023

31

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Controlled comparison of labetalol and propranolol in the management of severe hypertension

17 April 2023

32

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine

17 April 2023

33

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Effects of intravenous labetalol on blood pressure, angiotensin II and aldosterone in hypertension: comparison with propranolol

17 April 2023

34

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Vasodilating drugs: contrasting haemodynamic effects

17 April 2023

36

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Haemodynamic studies in hypertensive patients treated by oral propranolol

17 April 2023

38

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of "preinfarction" angina

17 April 2023

40

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

A study of labetalol in patients of European, West Indian and West African origin

17 April 2023

41

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

Untoward effects associated with practolol administration: oculomucocutaneous syndrome

17 April 2023

42

1 reference

https://api.crossref.org/works/10.1016/0002-8703(79)90294-1

17 April 2023

Identifiers

1 reference

26 September 2017

1 reference